ATE404170T1 - Subkutanes verabreichungssystem, verfahren zur herstellung desselben und verwendung zur behandlung von mangelerscheinung des cholinergen nervensystems - Google Patents
Subkutanes verabreichungssystem, verfahren zur herstellung desselben und verwendung zur behandlung von mangelerscheinung des cholinergen nervensystemsInfo
- Publication number
- ATE404170T1 ATE404170T1 AT04720662T AT04720662T ATE404170T1 AT E404170 T1 ATE404170 T1 AT E404170T1 AT 04720662 T AT04720662 T AT 04720662T AT 04720662 T AT04720662 T AT 04720662T AT E404170 T1 ATE404170 T1 AT E404170T1
- Authority
- AT
- Austria
- Prior art keywords
- group
- producing
- treatment
- same
- subcutaneous administration
- Prior art date
Links
- 230000001713 cholinergic effect Effects 0.000 title 1
- 230000007812 deficiency Effects 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 210000000653 nervous system Anatomy 0.000 title 1
- 238000007920 subcutaneous administration Methods 0.000 title 1
- 239000011159 matrix material Substances 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
- Percussion Or Vibration Massage (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB0300942 | 2003-03-14 | ||
| IB0304945 | 2003-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE404170T1 true ATE404170T1 (de) | 2008-08-15 |
Family
ID=32992641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04720662T ATE404170T1 (de) | 2003-03-14 | 2004-03-15 | Subkutanes verabreichungssystem, verfahren zur herstellung desselben und verwendung zur behandlung von mangelerscheinung des cholinergen nervensystems |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20070059369A1 (enExample) |
| EP (2) | EP1603532B1 (enExample) |
| JP (1) | JP2006520378A (enExample) |
| KR (1) | KR20060023111A (enExample) |
| AT (1) | ATE404170T1 (enExample) |
| AU (1) | AU2004218896B2 (enExample) |
| BR (1) | BRPI0407818A (enExample) |
| CA (1) | CA2518883A1 (enExample) |
| CY (1) | CY1108482T1 (enExample) |
| DE (1) | DE602004015744D1 (enExample) |
| DK (1) | DK1603532T3 (enExample) |
| EA (1) | EA011169B1 (enExample) |
| ES (1) | ES2312981T3 (enExample) |
| IL (1) | IL170759A (enExample) |
| IS (1) | IS8067A (enExample) |
| MX (1) | MXPA05009626A (enExample) |
| NO (1) | NO20054258L (enExample) |
| NZ (1) | NZ542459A (enExample) |
| PL (1) | PL1603532T3 (enExample) |
| PT (1) | PT1603532E (enExample) |
| SI (1) | SI1603532T1 (enExample) |
| UA (1) | UA82226C2 (enExample) |
| WO (1) | WO2004080436A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2432556T3 (es) | 2004-08-04 | 2013-12-04 | Evonik Corporation | Métodos para fabricar dispositivos de suministro y sus dispositivos |
| US8124601B2 (en) * | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| US8956636B2 (en) * | 2008-04-18 | 2015-02-17 | Warsaw Orthopedic, Inc. | Methods and compositions for treating postoperative pain comprosing ketorolac |
| WO2011132157A1 (en) | 2010-04-22 | 2011-10-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Oral sustained release formulation of huperzine a |
| WO2013173096A2 (en) * | 2012-05-18 | 2013-11-21 | Insero Health Inc. | Conjugates of huperzine and analogs thereof |
| KR101811797B1 (ko) * | 2013-04-03 | 2017-12-22 | 동국제약 주식회사 | 도네페질을 포함하는 비경구투여용 약제학적 조성물 |
| JP7111375B2 (ja) * | 2017-10-19 | 2022-08-02 | 株式会社佐藤園 | 学習記憶能力増強組成物 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106979A (en) * | 1989-02-21 | 1992-04-21 | University Of Pittsburgh | Method for the synthesis of huperzine A and analogs thereof and compounds useful therein |
| CN1125725A (zh) * | 1994-12-28 | 1996-07-03 | 中国科学院上海药物研究所 | 一类海克林碱衍生物及它的用途 |
| FR2756493B1 (fr) * | 1996-12-02 | 2001-04-13 | Delab | Dispositif d'administration locale de formulations solides ou semi-solides |
| US6352715B1 (en) | 1998-02-19 | 2002-03-05 | Sagittarius Life Science Corp | Transdermal rate-controlled delivery of Huperzine A for treatment of alzheimer's disease |
| US6565874B1 (en) * | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
| CN1279065A (zh) | 1999-07-06 | 2001-01-10 | 青岛科达生物工程有限公司 | 一种治疗记忆障碍和老年痴呆的药物组合物 |
| CN1194688C (zh) * | 2001-07-03 | 2005-03-30 | 山东绿叶制药股份有限公司 | 石杉碱甲及其衍生物或其盐的注射用缓释微球及其制备方法 |
| CN1383824A (zh) | 2002-05-21 | 2002-12-11 | 浙江省医学科学院 | 石杉碱鼻腔给药制剂 |
-
2004
- 2004-03-15 ES ES04720662T patent/ES2312981T3/es not_active Expired - Lifetime
- 2004-03-15 SI SI200430920T patent/SI1603532T1/sl unknown
- 2004-03-15 JP JP2006506340A patent/JP2006520378A/ja active Pending
- 2004-03-15 EA EA200501433A patent/EA011169B1/ru not_active IP Right Cessation
- 2004-03-15 KR KR1020057016999A patent/KR20060023111A/ko not_active Ceased
- 2004-03-15 BR BRPI0407818-7A patent/BRPI0407818A/pt not_active IP Right Cessation
- 2004-03-15 EP EP04720662A patent/EP1603532B1/en not_active Expired - Lifetime
- 2004-03-15 UA UAA200509681A patent/UA82226C2/uk unknown
- 2004-03-15 AU AU2004218896A patent/AU2004218896B2/en not_active Ceased
- 2004-03-15 DE DE602004015744T patent/DE602004015744D1/de not_active Expired - Lifetime
- 2004-03-15 DK DK04720662T patent/DK1603532T3/da active
- 2004-03-15 EP EP08159962A patent/EP1977735A1/en not_active Withdrawn
- 2004-03-15 WO PCT/IB2004/000734 patent/WO2004080436A1/en not_active Ceased
- 2004-03-15 PT PT04720662T patent/PT1603532E/pt unknown
- 2004-03-15 CA CA002518883A patent/CA2518883A1/en not_active Abandoned
- 2004-03-15 US US10/549,167 patent/US20070059369A1/en not_active Abandoned
- 2004-03-15 MX MXPA05009626A patent/MXPA05009626A/es active IP Right Grant
- 2004-03-15 NZ NZ542459A patent/NZ542459A/en unknown
- 2004-03-15 AT AT04720662T patent/ATE404170T1/de not_active IP Right Cessation
- 2004-03-15 PL PL04720662T patent/PL1603532T3/pl unknown
-
2005
- 2005-09-08 IL IL170759A patent/IL170759A/en not_active IP Right Cessation
- 2005-09-15 NO NO20054258A patent/NO20054258L/no not_active Application Discontinuation
- 2005-10-11 IS IS8067A patent/IS8067A/is unknown
-
2008
- 2008-11-06 CY CY20081101257T patent/CY1108482T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL170759A (en) | 2010-06-16 |
| EA011169B1 (ru) | 2009-02-27 |
| EP1977735A1 (en) | 2008-10-08 |
| EP1603532A1 (en) | 2005-12-14 |
| DK1603532T3 (da) | 2008-12-08 |
| AU2004218896A1 (en) | 2004-09-23 |
| HK1089085A1 (zh) | 2006-11-24 |
| ES2312981T3 (es) | 2009-03-01 |
| NZ542459A (en) | 2008-12-24 |
| AU2004218896B2 (en) | 2010-04-01 |
| SI1603532T1 (sl) | 2009-02-28 |
| DE602004015744D1 (de) | 2008-09-25 |
| IS8067A (is) | 2005-10-11 |
| CA2518883A1 (en) | 2004-09-23 |
| US20070059369A1 (en) | 2007-03-15 |
| EA200501433A1 (ru) | 2006-02-24 |
| PL1603532T3 (pl) | 2009-02-27 |
| CY1108482T1 (el) | 2014-04-09 |
| NO20054258D0 (no) | 2005-09-15 |
| WO2004080436A1 (en) | 2004-09-23 |
| MXPA05009626A (es) | 2005-10-18 |
| NO20054258L (no) | 2005-11-24 |
| EP1603532B1 (en) | 2008-08-13 |
| PT1603532E (pt) | 2008-11-20 |
| JP2006520378A (ja) | 2006-09-07 |
| BRPI0407818A (pt) | 2006-02-14 |
| KR20060023111A (ko) | 2006-03-13 |
| UA82226C2 (uk) | 2008-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108482T1 (el) | Συστημα υποδοριας διανομης, μεθοδος παρασκευης του και χρηση του για την αγωγη διαταραχων xολινεργικης ανεπαρκειας | |
| BR0215429A (pt) | Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente | |
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| TR200201430T2 (tr) | Antiproliferatif maddeler olarak faydalı yeni benzoimidazol türevleri. | |
| ATE228832T1 (de) | System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung | |
| CY1107452T1 (el) | Διαδερμικη μορφη χορηγησης για τη θεραπεια του συνδρομου ανησυχων ποδιων | |
| ATE267798T1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
| UA85708C2 (ru) | Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей | |
| HUT77627A (hu) | 2,2-Diklór-alkánkarbonsavak, eljárás előállításukra és ezeket tartalmazó, inzulinrezisztencia kezelésére alkalmazható gyógyszerkészítmények | |
| DE60203847D1 (de) | Verbindungen enthaltend S-Tofisopam sowie Verwendung dieser Verbindungen zur Herstellung eines Medikamentes zur Behandlung oder Prophylaxe von Krämpfen und Anfällen | |
| DE602004015406D1 (de) | Verwendung von 3-methoxy-pregnenolon bei der herstellung eines arzneimittels zur behandlung von neurodegenerativen erkrankungen | |
| ATE369348T1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| DE60004671D1 (de) | Neue piperazinylalkylthiopyrimidine derivate, diese enthaltende pharmazeutische zusammenstellungen und verfahren zu deren herstellung | |
| DE60323510D1 (de) | Implantat für den transport und die freigabe von pharmakologisch aktiven substanzen | |
| ATE281841T1 (de) | Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen | |
| ATE294582T1 (de) | Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs | |
| ATE417831T1 (de) | Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel | |
| DE69930624D1 (de) | Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie | |
| MY146802A (en) | Novel drugs for treating respiratory diseases | |
| DE69619868D1 (de) | Piperazinylalkylthiopyrimidin derivate, diese enthaltende pharmazeutische zusammensetzungen und verfahren zu deren herstellung | |
| DE50108711D1 (de) | Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz | |
| DE69926357D1 (de) | Vorbereitung eines medikaments zur behandlung von refluxösophagitis | |
| BR0210407A (pt) | Composto, composição farmacêutica, uso de um composto e método de tratamento de um distúrbio ou de uma doença de corpo animal vivo, incluindo um humano | |
| UA36167A (uk) | Спосіб лікування панкреатиту | |
| TH25772A (th) | การใช้ 3,4 ไดเฟนิลโครมานในการผลิตสารผสม?ทางเภสัชศาสตร์เพื่อใช้รักษาหรือป้องกันภาวะ?นมโตในผู้ชายซึ่งเกิดขึ้นเองหรือเกิดจาก?สาเหตุทางสรีรวิทยา |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1603532 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |